請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71814
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 忻凌偉 | |
dc.contributor.author | Hao-Yu Hsieh | en |
dc.contributor.author | 謝皓宇 | zh_TW |
dc.date.accessioned | 2021-06-17T06:10:45Z | - |
dc.date.available | 2019-03-05 | |
dc.date.copyright | 2019-03-05 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-11-13 | |
dc.identifier.citation | 1. Vaquero, J. J.; Kinahan, P. Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems. Annu. Rev. Biomed. Eng. 2015, 17, 385-414.
2. Wimalasena, K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med. Res. Rev. 2011, 31, 483-519. 3. German, C. L.; Baladi, M. G.; McFadden, L. M.; Hanson, G. R.; Fleckenstein, A. E. Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease. Pharmacol. Rev. 2015, 67, 1005-24. 4. Villemagne, V. L.; Okamura, N.; Pejoska, S.; Drago, J.; Mulligan, R. S.; Chetelat, G.; Ackermann, U.; O'Keefe, G.; Jones, G.; Gong, S.; Tochon-Danguy, H.; Kung, H. F.; Masters, C. L.; Skovronsky, D. M.; Rowe, C. C. In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. Arch. Neurol. 2011, 68, 905-12. 5. Dean, M.; Sung, V. W. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug. Des. Devel. Ther. 2018, 12, 313-319. 6. Jankovic, J.; Beach, J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48, 358-362. 7. Kenney, C.; Hunter, C.; Jankovic, J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord. 2007, 22, 193-7. 8. Scorr, L. M.; Factor, S. A. VMAT2 inhibitors for the treatment of tardive dyskinesia. J. Neurol. Sci. 2018, 389, 43-47. 9. Xenazine (tetrabenazine) Tablets, for Oral Use. Full Prescribing Information. Revised: 6/2015 . H. Lundbeck A/S. Retrieved 9 December 2015 10. Erickson, J. D.; Schafer, M. K.; Bonner, T. I.; Eiden, L. E.; Weihe, E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA 1996, 93, 5166-71. 11. Scherman, D.; Jaudon, P.; Henry, J. P. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. Proc. Natl. Acad. Sci. USA 1983, 80, 584-8. 12. Kilbourn, M.; Lee, L.; Vanderborght, T.; Jewett, D.; Frey, K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur. J. Pharmacol. 1995, 278, 249-252 13. DaSilva JN, Kilbourn MR, Mangner TJ. Synthesis of a [11C]methoxy derivative of alphadihydrotetrabenazine: A radio ligand for studying the vesicular monoamine transporter. Appl. Radiat. Isot. 1993, 44, 1487–1489 14. Vander Borght, T. M.; Sima, A. A. F.; Kilbourn, M. R.; Desmond, T. J.; Kuhl, D. E.; Frey, K. A. [3H]methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity. Neuroscience 1995, 68, 955-962. 15. Vander Borght, T. M.; Kilbourn, M. R.; Koeppe, R. A.; DaSilva, J. N.; Carey, J. E.; Kuhl, D. E.; Frey, K. A. In vivo imaging of the brain vesicular monoamine transporter. J. Nucl. Med. 1995, 36, 2252-60. 16. Lee, L. C.; Vander Borght, T.; Sherman, P. S.; Frey, K. A.; Kilbourn, M. R. In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter. J. Med. Chem. 1996, 39, 191-6. 17. Darchen, F.; Scherman, D.; Laduron, P. M.; Henry, J. P. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol. Pharmacol. 1988, 33, 672-7. 18. Clarke I, Turtle R, Johnston G, inventors. Cambridge Laboratories Limited, UK, assignee. Dihydrotetrabenazines and pharmaceutical compositions containing them WO 2005077946A1. Aug 25, 2005. 19. Saner, A.; Pletscher, A. A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover. J. Pharmacol. Exp. Ther. 1977, 203, 556-63. 20. Canney DJ, Guo YZ, Kung MP, Kung HF. Synthesis and preliminary evaluation of an iodovinyltetrabenazine analog as a marker for the vesicular monoamine transporter. J. Labelled Compd. Radiopharm 1993, 33, 355–368. 21. Kung, M. P.; Canney, D. J.; Frederick, D.; Zhuang, Z.; Billings, J. J.; Kung, H. F. Binding of 125I-iodovinyltetrabenazine to CNS vesicular monoamine transport sites. Synapse 1994, 18, 225-32 22. Canney, D. J.; Kung, M.-P.; Kung, H. F. Amino- and amido-tetrabenazine derivatives: Synthesis and evaluation as potential ligands for the vesicular monoamine transporter. Nuclear Medicine and Biology 1995, 22, 527-535. 23. Goswami, R.; Ponde, D. E.; Kung, M. P.; Hou, C.; Kilbourn, M. R.; Kung, H. F. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nuclear Medicine and Biology 2006, 33, 685-694. 24. Kung, M. P.; Hou, C.; Goswami, R.; Ponde, D. E.; Kilbourn, M. R.; Kung, H. F. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl. Med. Biol. 2007, 34, 239-46. 25. Kung, H. F.; Lieberman, B. P.; Zhuang, Z. P.; Oya, S.; Kung, M. P.; Choi, S. R.; Poessl, K.; Blankemeyer, E.; Hou, C.; Skovronsky, D.; Kilbourn, M. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine. Nucl. Med. Biol. 2008, 35, 825-37. 26. A Trial of 18F-AV-133 Positron Emission Tomography (PET) Imaging to Differentiate Subjects With Parkinson's Disease (PD) From Other Movement Disorders.; https://clinicaltrials.gov/ct2/show/NCT01550484 27. 曹馨心,長庚大學醫學物理暨影像科學研究所碩士論文,98年7月,9-Fluoropropyl-(+)-dihydrotetrabenazine [FP-(+)-DTBZ] 與大鼠第二型囊泡單胺轉運體之結合研究。 28. Yao, Z.; Wei, X.; Wu, X.; Katz, J. L.; Kopajtic, T.; Greig, N. H.; Sun, H. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur. J. Med. Chem. 2011, 46, 1841-8. 29. Brossi, A.; Lindlar, H.; Walter, M.; Schnider, O. Syntheseversuche in der Emetin Reihe 1. Mitteilung 2-Oxo-hydrobenzo[a]chinolizine. Helv. Chim. Acta. 1958, 41, 119-139; U.S. 2830993 (1958 to Hoffmann-La Roche). 30. Openshaw, H. T.; Whittaker, N. The synthesis of emeticne and related compounds. Part IV. A new synthesis of 3-substituted 1,2,3,4,6,7-hexahydro-9,10-dimethoxy- 2-oxo-11bH-benzo[a]-quinolizines. J. Chem. Soc. 1963, 1449-1460. 31. Kevin Mcgee , Bin-Feng LI, inventors. Neurocrine Biosciences, Inc. Limited, US, assignee. Synthetic methods for preparation of (s)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) WO2017112857A1, Jun 29, 2017 32. Rishel, M. J.; Amarasinghe, K. K.; Dinn, S. R.; Johnson, B. F. Asymmetric synthesis of tetrabenazine and dihydrotetrabenazine. J. Org. Chem. 2009, 74, 4001-4. 33. Kilbourn, M. R.; Lee, L. C.; Heeg, M. J.; Jewett, D. M. Absolute configuration of (+)-α-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality 1997, 9, 59-62. 34. Boldt, K. G.; Biggers, M. S.; Phifer, S. S.; Brine, G. A.; Rehder, K. S. Synthetic Communications 2009, 39, 3574. 35. Yu, Q. S.; Luo, W.; Deschamps, J.; Holloway, H. W.; Kopajtic, T.; Katz, J. L.; Brossi, A.; Greig, N. H. ACS Med. Chem. Lett. 2010, 1, 105. 36. Paek, S. M.; Kim, N. J.; Shin, D.; Jung, J. K.; Jung, J. W.; Chang, D. J.; Moon, H.; Suh, Y. G. Chem. Eur. J. 2010, 16, 4623. 37. Son, Y. W.; Kwon, T. H.; Lee, J. K.; Pae, A. N.; Lee, J. Y.; Cho, Y. S.; Min, S. J. Org. Lett. 2011, 13, 6500. 38. Johannes, M.; Altmann, K. H. Org. Lett. 2012, 14, 3752. 39. Siva Senkar Reddy, N.; Srinivas Reddy, A.; Yadav, J. S.; Subba Reddy, B. V. Tetrahedron Letters 2012, 53, 6916. 40. Orgren, L. R.; Maverick, E. E.; Marvin, C. C. J Org Chem 2015, 80, 12635. 41. Chen, W.; Seidel, D. Org. Lett. 2016, 18, 1024. 42. Fujii, A.; Hashiguchi, S.; Uematsu, N.; Ikariya, T.; Noyori, R. Journal of the American Chemical Society 1996, 118, 2521. 43. Ihara, M.; Takahashi, M.; Taniguchi, N.; Yasui, K.; Fukumoto, K. Asymmetric syntheses of chiral propane-I ,3-diols starting from malonic acid. J. Chem. Soc. Perkin Trans. 1989, 1, 897-903. 44. Onda, M.; Sugama, Y.; Yabuki, R. Methylation of the cyclic enamino ketones. Heterocycles. 1985, 23, 111-116. 45. 劉易霖,國立台灣大學醫學院藥學研究所碩士論文,100年7月,第二部分:(+)-α-Dihydrotetrabenazine之不對稱合成 46. Wiktelius, D.; Larsson, E. K.; Luthman, K. Chemoenzymatic synthesis of enantiomerically enriched α-chiral 3-oxy-propionaldehydes by lipase-catalyzed kinetic resolution and desymmetrization. Tetrahedron: Asymmetry 2006, 17, 2088-2100. 47. Tietze, L. F.; Rackelmann, N.; Sekar, G. Catalyst-controlled stereoselective combinatorial synthesis. Angew Chem Int Ed Engl 2003, 42, 4254. 48. Ohkuma, T.; Utsumi, N.; Tsutsumi, K.; Murata, K.; Sandoval, C.; Noyori, R. The hydrogenation/transfer hydrogenation network: asymmetric hydrogenation of ketones with chiral eta6-arene/N-Tosylethylenediamine-ruthenium(II) catalysts. J Am Chem Soc 2006, 128, 8724-5. 1. Parhi, A. K.; Wang, J. L.; Oya, S.; Choi, S. R.; Kung, M. P.; Kung, H. F. 2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents. J. Med. Chem. 2007, 50, 6673-84. 2. Stephen, H. A new synthesis of aldehydes. J. Chem. Soc., Trans. 1925, 127, 1874-1877. 3. Sonn, A and Müller, E Ber. deut. Chem. Ges. 1919, 52, 1927. 4. Azarifar, D.; Khosravi, K.; Soleimanei, F. Stannous Chloride Dihydrate: A Novel and Efficient Catalyst for the Synthesis of gem-Dihydroperoxides from Ketones and Aldehydes. Synthesis 2009, 2009, 2553-2556. 5. Cho, C. S.; Kim, D. T.; Choi, H. J.; Kim, T. J.; Shim, S. C. Catalytic Activity of Tin(II) Chloride in Esterification of Carboxylic Acids with Alcohols. Bulletin of the Korean Chemical Society, 2002, 23, 539-540. 6. Jadhav, V.H.; Borate, H.B.; Wakharkar, R.D. A simple method for deprotection of tert-butyldimethylsilyl ethers by using stannous chloride under microwave condition. Ind. J. Chem., 2006, 45B, 322. 7. Kirti, S.N.; Bapurao, B.S.; Murlidhar, S.S. Microwave-assisted beckmann rearrangement of ketoximes using stannous(II) chloride in ionic liquid as an efficient catalyst. Lett. Org. Chem., 2011, 8, 274. 8. Bates, D.K.; Li, K. Stannous chloride-mediated reductive cyclization-rearrangement of nitroarenyl ketones. J. Org. Chem., 2002, 67, 8662. 9. Kundu, A.; Prabhakar, S.; Vairamani, M.; Roy, S. A novel copper(II)/tin(II) reagent for aqueous carbonyl allylation: In situ diagnostics of reactive organometallics in water. Organometallics, 1997, 16, 4796. 10. Wang, J.; Yuan, G.; Dong, C.Q. Novel ultrasonication-assisted carbonyl allylation mediated by SnCl2 in water. Chem. Lett., 2004, 33, 286. 11. Tan, X.H.; Shen, B.; Liu L.; Guo, Q.X. Novel carbonyl allylation mediated by SnCl2/Cu in water. Tetrahedron Lett., 2002, 43, 9373. 12. Tan, X.H.; Tao, C.Z.; Hou, Y.Q.; Luo, L.; Liu, L.; Guo, Q.X. Use of cyclic allylic bromides in the SnCl2/Cu-mediated aqueous carbonyl allylation reaction. Chin. J. Chem., 2005, 23, 237. 13. Tan, X.H.; Shen, B.; Deng, W.; Zhao, H.; Liu, L.; Guo, Q.X. Novel carbonyl allylation mediated by SnCl2/TiCl3 in water. Org. Lett., 2003, 5, 1833. 14. Singh, O. M.; Devi, N. S. Stannous Chloride–Promoted Synthesis of S-Allyl-N-aryl Dithiocarbamates under Solvent-Free Conditions. Synthetic Communications 2011, 41, 516-522. 15. Kundu, A.; Prabhakar, S.; Vairamani, M.; Roy S. A novel copper(II)/tin(II) reagent for regio- and chemoselective carbonyl propargylation. Organometallics, 1999, 18, 2782. 16. Li, Q. R.; Gu, C. Z.; Yin, H. Tin-Indium Mediated and Microwave Assisted Propargylation of Aldehydes with Propargyl Bromide Chinese J Chem 2006, 24, 72-78. 17. Russowsky, D.; Lopes, F.A.; da Silva, V.S. S.; Canto, K.F. S.; D’Oca, M.G. M.; Godoi M.N. Multicomponent Biginelli’s synthesis of 3,4-dihydropyrimidin-2(1H)-ones promoted by SnCl2.2H2O. J. Braz. Chem. Soc., 2004, 15, 165. 18. Shailaja, M.; Manjula, A.; Rao, B.V.; Parvathi, N. Simple protocol for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones using SnCl2·2H2O-LiCl as an inexpensive catalyst system. Synth. Comm., 2004, 34, 1559. 19. Singh, O.M.; Devi, N.S. Application of β-Oxodithioesters in domino and multicomponent reactions: Facile route to dihydropyrimidines and coumarins. J. Org. Chem., 2009, 74, 3141. 20. Wang, M.; Song, Z.G.; Wan, X.; Zhao, S. SnCl2-catalyzed threecomponent one-pot Mannich-type reaction: efficient synthesis of β-aminocarbonyl compounds. Monatsh. Chem., 2009, 140, 1205. 21. Zhao, X.L.; Liu, L.; Chen, Y.J.; Wang, D. Three-Component barbier allylation-friedel-crafts alkylation promoted by BuPyCl/SnCl2·2H2O: Application to the synthesis of 4-(substituted phenyl)chromans. Chin. J. Chem., 2007, 25, 1312. 22. Yoo, C.L.; Fettinger J.C.; Kurth, M.J. Stannous chloride in alcohol: A one-pot conversion of 2-nitro-N-arylbenzamides to 2,3-dihydro-1H-quinazoline-4-ones. J. Org. Chem., 2005, 70, 6941. 23. Wang, M.; Song, Z.; Zhang T. SnCl2·2H2O-catalyzed one-pot synthesis of 4(3H)-quinazolinones from anthranilic acid, ortho esters, and amines under solvent free conditions. J. Heterocycl. Chem., 2010, 47, 468. 24. Shi, D.Q.; Dou, G.L.; Ni, S.N.; Shi, J.W.; Li, X.Y. An efficient synthesis of quinoxaline derivatives mediated by stannous chloride. J. Heterocycl. Chem., 2008, 1797. 25. McNaughton, B.R. ; Miller, B.L. A mild and efficient one-step synthesis of quinolines. Org. Lett., 2003, 5, 23, 4257. 26. Venkatesan, H.; Hocutt, F.M.; Jones, T.K.; Rabinowitz, M.H. A one-step synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid esters from o-nitrobenzaldehydes. J. Org. Chem., 2010, 75, 3488 27. Barros, A. I. R. N. A.; Silva, A. M. S. One-pot synthesis of 2-(2-hydroxyaryl)quinolines: reductive coupling reactions of 2′-hydroxy-2-nitrochalcones. Tetrahedron Letters 2003, 44, 5893-5896. 28. Madapa, S.; Singh, V.; Batra, S. An alternate approach to quinoline architecture via Baylis–Hillman chemistry: SnCl2-mediated tandem reaction toward synthesis of 4-(substituted vinyl)-quinolines. Tetrahedron 2006, 62, 8740-8747. 29. Selvam, N. P.; Babu, T. H.; Perumal, P. T. A simple and convenient approach to the Friedländer synthesis of pyrano[2,3-b]pyridines. Tetrahedron 2009, 65, 8524-8530. 30. Suresh, R.; Muthusubramanian, S.; Senthilkumaran, R.; Manickam, G. SnCl2-catalyzed selective atom economic imino Diels-Alder reaction: synthesis of 2-(1H-pyrrolo[2,3-b]pyridin-3-yl)quinolines. J. Org. Chem. 2012, 77, 1468-76. 31. Wu, Z.; Rea, P.; Wickham, G. ‘One-pot’ nitro reduction–cyclisation solid phase route to benzimidazoles. Tetrahedron Letters 2000, 41, 9871-9874. 32. Cho, C.S.; Kim, D.T.; Zhang, J.Q.; Ho, S.L.; Kim, T.J.; Shim S.C. Tin(II) chloride-mediated synthesis of 2-substituted benzoxazoles. J. Heterocycl. Chem., 2002, 3, 421 33. Bellamy, F. D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron Letters 1984, 25, 839-842. 34. Gersch, B.; Lehn, J.-M.; Grell, E. Synthesis of new dibenzo-diaza-crown ethers. Tetrahedron Letters 1996, 37, 2213-2216. 35. Boyer, G.; Miloudi, A.; El Abed, D.; Boyer, G.; Galy, J.-P. Reduction of Nitroindazoles: Preparation of New Amino and Chloroamino Derivatives. Heterocycles 2006, 68, 2595 - 2605 36. Bouissane, L.; Kazzouli, S. E.; Léger, J.-M.; Jarry, C.; Rakib, E. M.; Khouili, M.; Guillaumet, G. New and efficient synthesis of bi- and trisubstituted indazoles. Tetrahedron 2005, 61, 8218-8225. 37. Abbassi, N.; Rakib, E. M.; Bouissane, L.; Hannioui, A.; Khouili, M.; El Malki, A.; Benchidmi, M.; Essassi, E. M. Studies on the Reduction of the Nitro Group in 4-Nitroindazoles by Anhydrous SnCl2 in Different Alcohols. Synthetic Communications 2011, 41, 999-1005. 38. Abbassi, N.; Rakib, E.; Hannioui, A.; Alaoui, M.; Benchidmi, M.; Essassi, E.; Geffken, D. Alkylation and Reduction of N-Alkyl-4-nitroindazoles with Anhydrous SnCl2 in Ethanol: Synthesis of Novel 7-Ethoxy-N-alkylindazole Derivatives. Heterocycles 2011, 83, 891-900. 39. Kouakou, A.; Chicha, H.; Rakib, E. M.; Gamouh, A.; Hannioui, A.; Chigr, M.; Viale, M. SnCl2/RSH: a versatile catalytic system for the synthesis of 4-alkylsulfanyl-indazole derivatives. Journal of Sulfur Chemistry 2014, 36, 86-95. 40. Chicha, H.; Bouissane, L.; El Ammari, L.; Saadi, M.; Baltas, M.; El Mostapha, R. SnCl2/EtOH-Mediated Synthesis of Novel 4-Ethoxy- and 4-Chloroindazoles Bearing Sulfonamide Moieties. Synthetic Communications 2015, 45, 2005-2013. 41. Muathen, H. A. Oxidative Halogenation of Aromatic Compounds with Metal Halides and Sodium Bismuthate. Helv Chim Acta 2003, 86, 164-168. 42. Kumar, A.; Bhakuni, B. S.; Prasad, C. D.; Kumar, S.; Kumar, S. Potassium tert-butoxide-mediated synthesis of unsymmetrical diaryl ethers, sulfides and selenides from aryl bromides. Tetrahedron 2013, 69, 5383-5392. 43. Yuan, H.; Beard, R. L.; Liu, X. X.; Donello, J. E.; Viswanath, V.; Garst, M. E. Benzofuran-2-sulfonamides derivatives as chemokine receptor modulators. US20130231338 A1, Sep 5, 2013. 44. Bonnet, B.; Soullez, D.; Davioud-Charvet, E.; Landry, V.; Horvath, D.; Sergheraert, C.; New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase. Bioorg. Med. Chem. 1997, 7, 1249-1256. 45. Liu, C.; Zang, X.; Yu, B.; Yu, X.; Xu, Q. An efficient synthesis of unsymmetrical daiaryl thionethers. Synlett. 2011, 8, 1143–1148. 46. Moore, G. G. I.; Kenneth, H. J. Werkwijze ter bereiding van een herbicide verbinding. DE2118190 A1, Mar 9, 1972. 47. Pelz, K., Ernest, I.; Adlerová, E.; Metyšová J.; Protiva M. Neurotrope und psychotrope substanzen XXII. Weitere chlorderivate des 10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepins und einige verwandte stoffe. Collect. Czech. Chem. Commun. 1968, 33, 1852-1872. 48. Zienkiewicz, J.; Kaszynski, P. Fused-ring thiadiazines: preparation and crystallographic characterization of 3-phenyl derivative of benzo-, pyridio[2,3-e]-,pyrazino[2,3-e]-, and tetrafluorobenzo-[1,2,4]thiadiazines. J. Org. Chem. 2004, 69, 2551-2561. 49. Crosignani, S.; Prêtre, A.; Jorand-Lebrun, C.; Fraboulet, G.; Seenisamy, J.; Augustine, J. K.; Missotten, M., Humbert, Y.; Cleva, C.; Abla, N.; Daff, H.; Schott, O.; Schneider, M.; Burgat-Charvillon, F.; Rivron, D.; Hamernig, I.; Arrighi,J. F.; Gaudet, M.; Zimmerli, S. C.; Juillard, P.; Johnson, Z. Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases. J. Med. Chem. 2011, 54, 7299-7317. 50. Otsubo, K.; Ochi, Y.; Nakai, M.; Mori, A. Quinolone compound and pharmaceutical composition. WO2008150029 A1, Dec 11, 2008. 51. Itoh, T.; Mase, T. A general palladium-catalyzed coupling of aryl bromides/triflates and thiols. Org. Lett. 2004, 6, 4587-4590. 52. Khalfina, I. A.; Rogozhnikova, O. Y.; Vlasov, V. M. Nucleophilic substitution of nitro group in 3,5-dinitrobenzotrifluoride. Russ. J. Org. Chem. 1996, 32, 1325-1331. 53. Wassmundt, F. W.; Pedemonte, R. P. An improved synthesis of dibenzofurans by a free-radical. J. Org. Chem. 1996, 60, 4991-4994. 54. Wang, M.; Gao, M.; Hutchins, G. D.; Zheng Q. H. Synthesis of [11C]FEDAA1106 as a new PET imaging probe of peripheral benzodiazepine receptor expression. Eur. J. Med. Chem. 2009, 44, 2748–2753. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71814 | - |
dc.description.abstract | 單胺神經遞質為在人體中控制情緒、認知、記憶的重要調控分子。其結構常為一個單胺接上兩個碳之碳鍊再接上芳香環。常見的有多巴胺、血清素、正腎上腺素。調節這些單胺神經遞質的方式最常見的是以單胺轉運蛋白來作調控。在神經中常見的單胺轉運單白分別有多巴胺轉運蛋白(DAT)、血清素轉運蛋白(SERT)、正腎上腺素轉運蛋白(NET)、囊泡單胺轉運蛋白二型(VMAT2)。前三者之作用為將單胺神經遞質從突觸空間轉運至突觸前神經元,後者則將單胺神經遞質從細胞質轉運至突觸囊泡中。這對於單胺神經遞質有非常重要的調節作用。VMAT2已被證明可導致許多臨床神經系統疾病,包括藥物成癮,情緒障礙和壓力,以及帕金森氏症(Parkinson's Disease,PD)和阿茲海默症(Alzheimer's disease,AD)。但目前只知道帕金森氏症、阿茲海默症與VMAT2有關聯,但其中詳細關連並不清楚。而Tetrabenazine是目前美國FDA唯一允許用於治療亨丁頓舞蹈症的藥物,其對於VMAT2具有極高的親合力,其特定構型的代謝物(+)-DTBZ對於VMAT2之親合力為0.97 nM,如何得到(+)-TBZ即為一重要的課題。利用選擇性血清素回收抑制劑 (SSRI)為抑制血清素轉運蛋白的方法。若在其主結構二苯硫苯胺之胺基對位上具有氯原子,其可以增強SSRI對於SERT的抑制效果與加強其選擇性。但若在二苯硫苯胺之結構上以目前已知之氯化反應方法均不能選擇性的在胺之對位上氯化。本實驗室在以氯化亞錫還原硝基時發現了其副反應為在還原後的胺基對位上接上了氯原子,故嘗試以此為基礎來發展在二苯硫苯胺上胺基對位氯化之方法。本研究成功地以不對稱合成得到了(+)-TBZ並探討其應用,也在多種實驗條件下找出一鍋化還原氯化反應的最佳條件。 | zh_TW |
dc.description.abstract | Monoamine neurotransmitters are important regulatory molecules that control emotion, cognition, and memory in human brain. The structure is usually a monoamine with two carbon chains attached to the end of the aromatic ring. Dopamine, serotonin, and norepinephrine are common in humans. The most common way to regulate these monoamine neurotransmitters is by monoamine transporters. The monoamine transporters commonly found in nerves are dopamine transporter (DAT), serotonin transporter (SERT), norepinephrine transporter (NET), and vesicular monoamine transporter type 2 (VMAT2). The role of the first three is to transport monoamine neurotransmitters from the synaptic space to presynaptic neurons, the last one transport monoamine neurotransmitters from the cytoplasm to synaptic vesicles. This has a very important regulatory effect on monoamine neurotransmitters. VMAT2 has been shown to cause many clinical neurological diseases, including drug addiction, mood disorders and stress, as well as Parkinson's Disease (PD) and Alzheimer's disease (AD). However, only Parkinson's disease and Alzheimer's disease are currently associated with VMAT2, but the detailed relationship is not clear. Tetrabenazine is currently the only drug approved by the US FDA for the treatment of Huntington's disease. It has a very high affinity for VMAT2, and its specific configuration of the metabolite (+)-DTBZ has an affinity for VMAT2 of 0.97 nM. How to get (+)-TBZ is an important issue. A selective serotonin reuptake inhibitor (SSRI) is used as a method of inhibiting serotonin transporters. If it has a chlorine atom on the para position of the main structure of diphenylthioaniline, it can enhance the inhibitory effect of SSRI on SERT and enhance its selectivity. However, if the structure of diphenylthioaniline is chlorinated at the para position of the amine by the currently known chlorination reaction method. In our laboratory, when the nitro group was reduced by stannous chloride, a side reaction was found to be a chlorine atom attached to the amine group after the reduction. Therefore, based on this, an amine-based chlorination method on diphenylthioaniline was developed.
In this study, (+)-TBZ was successfully synthesized by asymmetric synthesis and its application was explored. The optimal conditions for one-pot reduction chlorination were also found under various experimental conditions. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:10:45Z (GMT). No. of bitstreams: 1 ntu-107-D99423001-1.pdf: 16401273 bytes, checksum: b6b0161bafe78f7d69b4f38684d4d46e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 i
致謝 ii 摘要 iii Abstract iv 目錄 vi 圖目錄 ix 表目錄 x 流程目錄 xi 實驗結果附圖目錄 xii 英文縮寫表 xviii 第一部分:Tetrabenazine之全合成研究 1 一:緒論 1 1.1 正子斷層掃描 (positron emission tomography, PET) 1 1.2 囊泡單胺轉運體 (vesicular monoamine transporter, VMAT) 2 1.3 Tetrabenazine合成方法之回顧 13 1.4 先前之研究 25 1.4.1 合成策略部分 25 1.4.2 光學活性分析部分 29 1.5 研究動機 37 二:實驗結果與討論 38 2.1不對稱全合成逆分析 38 2.2合成部分 39 2.3 光學活性分析 44 2.3.1 從TBZ到化合物103 44 2.3.2 化合物103立體位向之討論 50 2.4 結果與討論 60 三:結論 63 第一部分參考文獻 64 四:實驗部分 70 4.1 實驗藥品及溶劑 70 4.1.1 藥品及溶劑 70 4.1.2 自製無水溶劑 72 4.1.3 實驗儀器裝置 72 4.2 合成方式 74 五:光譜數據 92 5.1 NMR 92 5.2 HPLC相關 131 第二部分:SERTi之還原氯化研究 158 一:緒論 158 1.1 觀測到現象 158 1.2 氯化亞錫之反應類型回顧 158 1.2.1.官能基轉換 158 1.2.2. 多重分子反應 162 1.2.3. 雜環合成 163 1.3 硝基苯的還原取代反應回顧 165 1.4 先前團隊工作回顧 169 1.5 研究動機 174 1.5.1 VI A族元素的影響 174 二:結果與討論 177 2.1 測試化合物製備 177 2.2 還原氯化反應實驗 181 2.3 樣品處理與分析方法 181 2.4 實驗結果與討論 181 三: 結論 186 第二部分參考文獻 187 四:材料與方法 192 4.1 實驗材料 192 4.1.1 實驗藥品及溶劑來源 192 4.1.2 自製無水溶劑 193 4.2 合成方法 195 4.4 分析方法 202 4.4.1 HPLC-MS 202 4.4.2 GC 203 五:光譜數據 204 5.1 NMR 204 5.2 GC-LC對照 240 | |
dc.language.iso | zh-TW | |
dc.title | 單胺轉運蛋白抑制劑的合成研究 | zh_TW |
dc.title | Synthetic Study of Monoamine Transporter Inhibitor | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳基旺,梁碧惠,顧記華,陳繼明 | |
dc.subject.keyword | 單胺神經遞質,血清素,囊泡單胺轉運蛋白二型,亨丁頓舞蹈症,選擇性血清素回收抑制劑, | zh_TW |
dc.subject.keyword | monoamine neurotransmitter,serotonin,vesicular monoamine transporter type 2,selective serotonin reuptake inhibitor, | en |
dc.relation.page | 274 | |
dc.identifier.doi | 10.6342/NTU201804272 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-11-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 16.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。